“Lebrikizumab Confirms a Consistent Safety Profile in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis: ​ Data From 11 Trials With Over 3000 Patient-Years of Exposure”, J of Skin, vol. 9, no. 1, p. s511, Jan. 2025, doi: 10.25251/skin.9.supp.511.